POTASSIUM CHLORIDE EXTENDED RELEASE
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- POTASSIUM CHLORIDE EXTENDED RELEASE
- Generic name
- POTASSIUM CHLORIDE
- Manufacturer
- Granules Pharmaceuticals Inc.
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 9f8d2886-9ecd-4cbf-a84a-2d221cb3497c
- SPL ID
- f33d5a34-e5e7-a85f-e053-2995a90a6db3
- Version
- 10
- Effective date
- 2023-01-27
- Source export date
- 2026-09-28
- Source partition
- 7
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0007-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/bb1af06e95bcf9567b07e56fcf3a03c0cac3c7c82ff89d4c970881174949e5b7/drug-label-0007-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 05:44:03
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 211797 | derived:openfda.application_number |
| application number | ANDA211797 | openfda.application_number | |
| brand name | POTASSIUM CHLORIDE EXTENDED RELEASE | openfda.brand_name | |
| generic name | POTASSIUM CHLORIDE | openfda.generic_name | |
| manufacturer name | Granules Pharmaceuticals Inc. | openfda.manufacturer_name | |
| ndc | package | 70010-022-62 | openfda.package_ndc |
| ndc | package | 70010-021-05 | openfda.package_ndc |
| ndc | package | 70010-021-01 | openfda.package_ndc |
| ndc | package | 70010-022-05 | openfda.package_ndc |
| ndc | package | 70010-021-10 | openfda.package_ndc |
| ndc | package | 70010-022-10 | openfda.package_ndc |
| ndc | package | 70010-021-62 | openfda.package_ndc |
| ndc | package | 70010-022-61 | openfda.package_ndc |
| ndc | package | 70010-022-01 | openfda.package_ndc |
| ndc | package | 70010-021-61 | openfda.package_ndc |
| ndc | product | 70010-021 | openfda.product_ndc |
| ndc | product | 70010-022 | openfda.product_ndc |
| ndc11 | package | 70010002201 | derived:openfda.package_ndc |
| ndc11 | package | 70010002262 | derived:openfda.package_ndc |
| ndc11 | package | 70010002205 | derived:openfda.package_ndc |
| ndc11 | package | 70010002162 | derived:openfda.package_ndc |
| ndc11 | package | 70010002110 | derived:openfda.package_ndc |
| ndc11 | package | 70010002105 | derived:openfda.package_ndc |
| ndc11 | package | 70010002161 | derived:openfda.package_ndc |
| ndc11 | package | 70010002101 | derived:openfda.package_ndc |
| ndc11 | package | 70010002261 | derived:openfda.package_ndc |
| ndc11 | package | 70010002210 | derived:openfda.package_ndc |
| rxcui | 312529 | openfda.rxcui | |
| rxcui | 628953 | openfda.rxcui | |
| spl id | f33d5a34-e5e7-a85f-e053-2995a90a6db3 | id | |
| spl set id | 9f8d2886-9ecd-4cbf-a84a-2d221cb3497c | set_id | |
| unii | 660YQ98I10 | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS • Gastrointestinal Irritation: Take with meals ( 5.1 ) 5.1 Gastrointestinal Adverse Reactions Solid oral dosage forms of potassium chloride can produce ulcerative and/or stenotic lesions of the gastrointestinal tract, particularly if the drug maintains contact with the gastrointestinal mucosa for prolonged periods. Consider the use of liquid potassium in patients with dysphagia, swallowing disorders, or severe gastrointestinal motility disorders. If severe vomiting, abdominal pain, distention, or gastrointestinal bleeding occurs, discontinue potassium chloride extended-release tablets and consider possibility of ulceration, obstruction or perforation. Potassium chloride extended-release tablets should not be taken on an empty stomach because of its potential for gastric irritation [see Dosage and Administration (2.1) ].
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The following adverse reactions have been identified with use of oral potassium salts. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The most common adverse reactions to oral potassium salts are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea. There have been reports hyperkalemia and of upper and lower gastrointestinal condition including obstruction, bleeding, ulceration, perforation. Skin rash has been reported rarely. • The most common adverse reactions are nausea, vomiting, flatulence, abdominal pain/discomfort and diarrhea. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Granules Pharmaceuticals Inc., at 1-877-770-3183 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.